Published in Science on May 31, 2011
The perils of pathogen discovery: origin of a novel parvovirus-like hybrid genome traced to nucleic acid extraction spin columns. J Virol (2013) 3.37
Failure to confirm XMRV/MLVs in the blood of patients with chronic fatigue syndrome: a multi-laboratory study. Science (2011) 1.56
DNA extraction columns contaminated with murine sequences. PLoS One (2011) 1.55
In-depth investigation of archival and prospectively collected samples reveals no evidence for XMRV infection in prostate cancer. PLoS One (2012) 1.33
Benefit from B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A double-blind and placebo-controlled study. PLoS One (2011) 1.28
The National Heart, Lung, and Blood Institute retrovirus epidemiology donor studies (Retrovirus Epidemiology Donor Study and Retrovirus Epidemiology Donor Study-II): twenty years of research to advance blood product safety and availability. Transfus Med Rev (2012) 1.14
Multiple sources of contamination in samples from patients reported to have XMRV infection. PLoS One (2012) 1.08
XMRV and prostate cancer--a 'final' perspective. Nat Rev Urol (2012) 1.08
Recombinant origin, contamination, and de-discovery of XMRV. Curr Opin Virol (2012) 0.96
Xpr1 is an atypical G-protein-coupled receptor that mediates xenotropic and polytropic murine retrovirus neurotoxicity. J Virol (2011) 0.96
Chronic fatigue syndrome and subsequent risk of cancer among elderly US adults. Cancer (2012) 0.94
Restricted replication of xenotropic murine leukemia virus-related virus in pigtailed macaques. J Virol (2012) 0.93
Characterization, mapping, and distribution of the two XMRV parental proviruses. J Virol (2011) 0.93
EEG spectral coherence data distinguish chronic fatigue syndrome patients from healthy controls and depressed patients--a case control study. BMC Neurol (2011) 0.93
Retracted Identification of XMRV infection-associated microRNAs in four cell types in culture. PLoS One (2012) 0.89
No detection of XMRV in blood samples and tissue sections from prostate cancer patients in Northern Europe. PLoS One (2011) 0.89
Nucleic Acid, Antibody, and Virus Culture Methods to Detect Xenotropic MLV-Related Virus in Human Blood Samples. Adv Virol (2011) 0.87
Conference highlights of the 15th International Conference on Human Retrovirology: HTLV and related retroviruses, 4-8 June 2011, Leuven, Gembloux, Belgium. Retrovirology (2011) 0.87
Absence of XMRV and closely related viruses in primary prostate cancer tissues used to derive the XMRV-infected cell line 22Rv1. PLoS One (2012) 0.87
Membrane fusion and cell entry of XMRV are pH-independent and modulated by the envelope glycoprotein's cytoplasmic tail. PLoS One (2012) 0.85
No evidence for XMRV nucleic acids, infectious virus or anti-XMRV antibodies in Canadian patients with chronic fatigue syndrome. PLoS One (2011) 0.85
In vitro assembly of virus-like particles of a gammaretrovirus, the murine leukemia virus XMRV. J Virol (2011) 0.83
Phylogeny-directed search for murine leukemia virus-like retroviruses in vertebrate genomes and in patients suffering from myalgic encephalomyelitis/chronic fatigue syndrome and prostate cancer. Adv Virol (2011) 0.83
Zinc-finger antiviral protein inhibits XMRV infection. PLoS One (2012) 0.83
Detection of murine leukemia virus or mouse DNA in commercial RT-PCR reagents and human DNAs. PLoS One (2011) 0.83
Endogenous Murine Leukemia Viruses: Relationship to XMRV and Related Sequences Detected in Human DNA Samples. Adv Virol (2011) 0.82
Biochemical, inhibition and inhibitor resistance studies of xenotropic murine leukemia virus-related virus reverse transcriptase. Nucleic Acids Res (2011) 0.82
No evidence of murine leukemia virus-related viruses in live attenuated human vaccines. PLoS One (2011) 0.82
Prostate cancer: XMRV--contaminant, not cause? Nat Rev Urol (2011) 0.81
Development and application of a high-throughput microneutralization assay: lack of xenotropic murine leukemia virus-related virus and/or murine leukemia virus detection in blood donors. Transfusion (2012) 0.81
No biological evidence of XMRV in blood or prostatic fluid from prostate cancer patients. PLoS One (2012) 0.81
Identification of Pathogen Signatures in Prostate Cancer Using RNA-seq. PLoS One (2015) 0.81
Xenotropic murine leukemia virus-related virus is not associated with chronic fatigue syndrome in patients from different areas of the us in the 1990s. Virol J (2011) 0.80
Origin of XMRV and its demise as a human pathogen associated with chronic fatigue syndrome. Viruses (2011) 0.79
The saga of XMRV: a virus that infects human cells but is not a human virus. Emerg Microbes Infect (2014) 0.79
Structural and biochemical characterization of the inhibitor complexes of xenotropic murine leukemia virus-related virus protease. FEBS J (2011) 0.78
No evidence for the involvement of XMRV or MCV in the pathogenesis of breast cancer. Br J Cancer (2012) 0.78
Development of sensitive single-round pol or env RT-PCR assays to screen for XMRV in multiple sample types. J Virol Methods (2011) 0.78
Prevalence of XMRV nucleic acid and antibody in HIV-1-Infected men and in men at risk for HIV-1 Infection. Adv Virol (2011) 0.78
Susceptibility of human lymphoid tissue cultured ex vivo to xenotropic murine leukemia virus-related virus (XMRV) infection. PLoS One (2012) 0.78
Xenotropic Murine Leukemia Virus-Related Virus (XMRV) and the Safety of the Blood Supply. Clin Microbiol Rev (2016) 0.77
Generation of multiple replication-competent retroviruses through recombination between PreXMRV-1 and PreXMRV-2. J Virol (2013) 0.77
Intrinsic DNA synthesis fidelity of xenotropic murine leukemia virus-related virus reverse transcriptase. FEBS J (2012) 0.76
Xenotropic MLV envelope proteins induce tumor cells to secrete factors that promote the formation of immature blood vessels. Retrovirology (2013) 0.76
Partial molecular cloning of the JHK retrovirus using gammaretrovirus consensus PCR primers. Future Virol (2013) 0.75
XMRV and Public Health: The Retroviral Genome Is Not a Suitable Template for Diagnostic PCR, and Its Association with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Appears Unreliable. Front Public Health (2017) 0.75
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection. AIDS (2003) 5.28
Absence of evidence of xenotropic murine leukemia virus-related virus infection in persons with chronic fatigue syndrome and healthy controls in the United States. Retrovirology (2010) 3.64
The perils of pathogen discovery: origin of a novel parvovirus-like hybrid genome traced to nucleic acid extraction spin columns. J Virol (2013) 3.37
A novel rhabdovirus associated with acute hemorrhagic fever in central Africa. PLoS Pathog (2012) 2.63
Differential N-linked glycosylation of human immunodeficiency virus and Ebola virus envelope glycoproteins modulates interactions with DC-SIGN and DC-SIGNR. J Virol (2003) 2.42
Assessment of the ability of a fourth-generation immunoassay for human immunodeficiency virus (HIV) antibody and p24 antigen to detect both acute and recent HIV infections in a high-risk setting. J Clin Microbiol (2009) 2.18
Proteolysis of the Ebola virus glycoproteins enhances virus binding and infectivity. J Virol (2007) 2.16
The spread, treatment, and prevention of HIV-1: evolution of a global pandemic. J Clin Invest (2008) 2.12
The spike protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted by neutralizing antibodies. J Virol (2013) 2.10
Performance of the Celera Diagnostics ViroSeq HIV-1 Genotyping System for sequence-based analysis of diverse human immunodeficiency virus type 1 strains. J Clin Microbiol (2004) 2.01
A metagenomic analysis of pandemic influenza A (2009 H1N1) infection in patients from North America. PLoS One (2010) 1.99
DC-SIGN and DC-SIGNR interact with the glycoprotein of Marburg virus and the S protein of severe acute respiratory syndrome coronavirus. J Virol (2004) 1.92
Thermodynamically modulated partially double-stranded linear DNA probe design for homogeneous real-time PCR. Nucleic Acids Res (2007) 1.82
Evaluation of the sensitivity and specificity of six HIV combined p24 antigen and antibody assays. J Virol Methods (2004) 1.82
Use of a multifaceted approach to analyze HIV incidence in a cohort study of women in the United States: HIV Prevention Trials Network 064 Study. J Infect Dis (2012) 1.78
Impact of human immunodeficiency virus type 1 (HIV-1) genetic diversity on performance of four commercial viral load assays: LCx HIV RNA Quantitative, AMPLICOR HIV-1 MONITOR v1.5, VERSANT HIV-1 RNA 3.0, and NucliSens HIV-1 QT. J Clin Microbiol (2005) 1.75
Seroreversion in subjects receiving antiretroviral therapy during acute/early HIV infection. Clin Infect Dis (2006) 1.65
Endosomal proteolysis by cathepsins is necessary for murine coronavirus mouse hepatitis virus type 2 spike-mediated entry. J Virol (2006) 1.59
Characterization of antibodies elicited by XMRV infection and development of immunoassays useful for epidemiologic studies. Retrovirology (2010) 1.57
Failure to confirm XMRV/MLVs in the blood of patients with chronic fatigue syndrome: a multi-laboratory study. Science (2011) 1.56
HIV-infected cells are major inducers of plasmacytoid dendritic cell interferon production, maturation, and migration. Virology (2005) 1.54
Highly conserved regions within the spike proteins of human coronaviruses 229E and NL63 determine recognition of their respective cellular receptors. J Virol (2006) 1.49
A RealTime HIV-1 viral load assay for automated quantitation of HIV-1 RNA in genetically diverse group M subtypes A-H, group O and group N samples. J Virol Methods (2007) 1.47
Detection of individuals with acute HIV-1 infection using the ARCHITECT HIV Ag/Ab Combo assay. J Acquir Immune Defic Syndr (2009) 1.46
The prevalence of diverse HIV-1 strains was stable in Cameroonian blood donors from 1996 to 2004. J Acquir Immune Defic Syndr (2008) 1.46
The unexpected pleiotropic activities of RANTES. J Immunol (2009) 1.40
Estimation of HIV incidence in a large, community-based, randomized clinical trial: NIMH project accept (HIV Prevention Trials Network 043). PLoS One (2013) 1.40
Cleavage and activation of the severe acute respiratory syndrome coronavirus spike protein by human airway trypsin-like protease. J Virol (2011) 1.37
Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes. Emerg Infect Dis (2005) 1.36
alpha-Defensins can have anti-HIV activity but are not CD8 cell anti-HIV factors. AIDS (2003) 1.34
In-depth investigation of archival and prospectively collected samples reveals no evidence for XMRV infection in prostate cancer. PLoS One (2012) 1.33
Performance of the automated Abbott RealTime HIV-1 assay on a genetically diverse panel of specimens from Brazil. J Virol Methods (2006) 1.33
A single amino acid of the human immunodeficiency virus type 2 capsid affects its replication in the presence of cynomolgus monkey and human TRIM5alphas. J Virol (2007) 1.32
Evaluation of performance across the dynamic range of the Abbott RealTime HIV-1 assay as compared to VERSANT HIV-1 RNA 3.0 and AMPLICOR HIV-1 MONITOR v1.5 using serial dilutions of 39 group M and O viruses. J Virol Methods (2006) 1.31
Performance of the automated Abbott RealTime HIV-1 assay on a genetically diverse panel of specimens from London: comparison to VERSANT HIV-1 RNA 3.0, AMPLICOR HIV-1 MONITOR v1.5, and LCx HIV RNA Quantitative assays. J Virol Methods (2006) 1.30
Infection, viral dissemination, and antibody responses of rhesus macaques exposed to the human gammaretrovirus XMRV. J Virol (2011) 1.28
Experimental infection of rhesus macaques with West Nile virus: level and duration of viremia and kinetics of the antibody response after infection. J Infect Dis (2004) 1.25
Identification of HIV type 1 group N infections in a husband and wife in Cameroon: viral genome sequences provide evidence for horizontal transmission. AIDS Res Hum Retroviruses (2006) 1.24
Variations in plasmacytoid dendritic cell (PDC) and myeloid dendritic cell (MDC) levels in HIV-infected subjects on and off antiretroviral therapy. J Clin Immunol (2006) 1.23
Molecular characterization of 39 HIV isolates representing group M (subtypes A-G) and group O: sequence analysis of gag p24, pol integrase, and env gp41. AIDS Res Hum Retroviruses (2003) 1.23
Synergy or independence? Deciphering the interaction of HLA Class I and NK cell KIR alleles in early HIV-1 disease progression. PLoS Pathog (2007) 1.22
Concerns over the origin of NIH-CQV, a novel virus discovered in Chinese patients with seronegative hepatitis. Proc Natl Acad Sci U S A (2014) 1.21
Evaluation of a prototype Trypanosoma cruzi antibody assay with recombinant antigens on a fully automated chemiluminescence analyzer for blood donor screening. Transfusion (2006) 1.19
Similar changes in plasmacytoid dendritic cell and CD4 T-cell counts during primary HIV-1 infection and treatment. AIDS (2006) 1.16
Low-level HIV infection of plasmacytoid dendritic cells: onset of cytopathic effects and cell death after PDC maturation. Virology (2004) 1.16
Filoviruses utilize glycosaminoglycans for their attachment to target cells. J Virol (2013) 1.11
The effects of early antiretroviral therapy and its discontinuation on the HIV-specific antibody response. AIDS Res Hum Retroviruses (2006) 1.11
HIV infections in northwestern Cameroon: identification of HIV type 1 group O and dual HIV type 1 group M and group O infections. AIDS Res Hum Retroviruses (2004) 1.11
HIV pathogenesis: 25 years of progress and persistent challenges. AIDS (2009) 1.11
Characterization of Chikungunya pseudotyped viruses: Identification of refractory cell lines and demonstration of cellular tropism differences mediated by mutations in E1 glycoprotein. Virology (2009) 1.09
The signal peptide of the ebolavirus glycoprotein influences interaction with the cellular lectins DC-SIGN and DC-SIGNR. J Virol (2006) 1.09
Multicenter evaluation of a new, automated enzyme-linked immunoassay for detection of human immunodeficiency virus-specific antibodies and antigen. J Clin Microbiol (2004) 1.07
Analysis of insertions and deletions in the gag p6 region of diverse HIV type 1 strains. AIDS Res Hum Retroviruses (2004) 1.05
High CD8+ T cell activation marks a less differentiated HIV-1 specific CD8+ T cell response that is not altered by suppression of viral replication. PLoS One (2009) 1.02
HIV genotypes and primary drug resistance among HIV-seropositive blood donors in Brazil: role of infected blood donors as sentinel populations for molecular surveillance of HIV. J Acquir Immune Defic Syndr (2013) 1.00
Differential transmission of HIV traversing fetal oral/intestinal epithelia and adult oral epithelia. J Virol (2011) 0.99
HIV is inactivated after transepithelial migration via adult oral epithelial cells but not fetal epithelial cells. Virology (2010) 0.99
HIV surveillance in a large, community-based study: results from the pilot study of Project Accept (HIV Prevention Trials Network 043). BMC Infect Dis (2011) 0.97
Performance evaluation of the new fully automated human immunodeficiency virus antigen-antibody combination assay designed for blood screening. Transfusion (2008) 0.97
Natural suppression of human immunodeficiency virus type 1 replication is mediated by transitional memory CD8+ T cells. J Virol (2010) 0.96
HIV-1 strains identified in Brazilian blood donors: significant prevalence of B/F1 recombinants. AIDS Res Hum Retroviruses (2007) 0.96
Metabolic approaches to treatment of melanoma. Clin Cancer Res (2009) 0.95
Large-scale analysis of the prevalence and geographic distribution of HIV-1 non-B variants in the United States. J Clin Microbiol (2013) 0.95
A neutralizing monoclonal antibody targeting the acid-sensitive region in chikungunya virus E2 protects from disease. PLoS Negl Trop Dis (2013) 0.94
Identification and genomic sequence of an HIV type 1 group N isolate from Cameroon. AIDS Res Hum Retroviruses (2004) 0.94
Differential downregulation of ACE2 by the spike proteins of severe acute respiratory syndrome coronavirus and human coronavirus NL63. J Virol (2009) 0.94
Identification of human immunodeficiency virus type 1 non-B subtypes and antiretroviral drug-resistant strains in United States blood donors. Transfusion (2008) 0.93
Increased virus replication and virulence after serial passage of human immunodeficiency virus type 2 in baboons. J Virol (2003) 0.93
High Incidence of Chikungunya Virus and Frequency of Viremic Blood Donations during Epidemic, Puerto Rico, USA, 2014. Emerg Infect Dis (2016) 0.93
The CD8+ cell noncytotoxic anti-HIV response can be blocked by protease inhibitors. Proc Natl Acad Sci U S A (2003) 0.92
Analysis of pol integrase sequences in diverse HIV type 1 strains using a prototype genotyping assay. AIDS Res Hum Retroviruses (2009) 0.92
HIV/AIDS: 30 years of progress and future challenges. Eur J Immunol (2011) 0.90
IL-2 immunotherapy to recently HIV-1 infected adults maintains the numbers of IL-17 expressing CD4+ T (T(H)17) cells in the periphery. J Clin Immunol (2010) 0.89
Relationship of CD8(+) T cell noncytotoxic anti-HIV response to CD4(+) T cell number in untreated asymptomatic HIV-infected individuals. Blood (2002) 0.89
The first B/G intersubtype recombinant form of human immunodeficiency virus type 1 (HIV-1) identified in Germany was undetected or underquantitated by some commercial viral load assays. J Med Virol (2006) 0.88
Immunoblot assay using recombinant antigens as a supplemental test to confirm the presence of antibodies to Trypanosoma cruzi. Clin Vaccine Immunol (2007) 0.88
Absence of XMRV and closely related viruses in primary prostate cancer tissues used to derive the XMRV-infected cell line 22Rv1. PLoS One (2012) 0.87
Host genetic basis for hepatitis C virus clearance: a role for blood collection centers. Curr Opin Hematol (2010) 0.87
Human herpesvirus 6 infection mimicking juvenile myelomonocytic leukemia in an infant. J Pediatr Hematol Oncol (2002) 0.87
Analysis of HIV type 1 gp41 sequences in diverse HIV type 1 strains. AIDS Res Hum Retroviruses (2007) 0.87
Seroprevalence of xenotropic murine leukemia virus-related virus in normal and retrovirus-infected blood donors. Transfusion (2011) 0.87
HIV-1 Group N: evidence of ongoing transmission in Cameroon. AIDS Res Hum Retroviruses (2006) 0.87